Literature DB >> 28353017

Treatment of Young Adults with Acute Lymphoblastic Leukemia.

Ankit Kansagra1, Mark Litzow2.   

Abstract

Young adults with acute lymphoblastic leukemia are a distinctive category of patients, with substantial difference in disease biology and response to therapy; hence, they pose unique challenges and issues beyond those faced by children and older adults. Despite inferior survival compared to children, there is growing evidence to suggest that young adults have improved outcomes when treated with pediatric-based approaches. With better supportive care and toxicity management and multidisciplinary team and approach, we have made great improvement in outcomes of young adults with ALL. However, despite significant progress, patients with persistence of minimal residual disease have a poor prognosis. This review discusses current controversies in the management of young adults with ALL, outcomes following pediatric and adult protocols, and the role of allogeneic stem cell transplantation. We also explore recent advances in disease monitoring and highlight our approach to incorporation of novel therapies in the management of young adults with ALL.

Entities:  

Keywords:  Adolescent and young adults; Asparaginase; Hematopoietic stem cell transplant; Monoclonal antibodies; Philadelphia chromosome; Supportive care

Mesh：

Substances：

Year:  2017        PMID： 28353017     DOI： 10.1007/s11899-017-0377-y

Source DB:  PubMed          Journal:  Curr Hematol Malig Rep        ISSN： 1558-8211            Impact factor:   3.952


  62 in total

1.  Chimeric antigen receptor T cells for sustained remissions in leukemia.

Authors:  Shannon L Maude; Noelle Frey; Pamela A Shaw; Richard Aplenc; David M Barrett; Nancy J Bunin; Anne Chew; Vanessa E Gonzalez; Zhaohui Zheng; Simon F Lacey; Yolanda D Mahnke; Jan J Melenhorst; Susan R Rheingold; Angela Shen; David T Teachey; Bruce L Levine; Carl H June; David L Porter; Stephan A Grupp
Journal:  N Engl J Med       Date:  2014-10-16       Impact factor: 91.245

2.  Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.

Authors:  Naval Daver; Deborah Thomas; Farhad Ravandi; Jorge Cortes; Rebecca Garris; Elias Jabbour; Guillermo Garcia-Manero; Gautam Borthakur; Tapan Kadia; Michael Rytting; Marina Konopleva; Hagop Kantarjian; Susan O'Brien
Journal:  Haematologica       Date:  2015-02-14       Impact factor: 9.941

3.  Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols.

Authors:  Elly Barry; Daniel J DeAngelo; Donna Neuberg; Kristen Stevenson; Mignon L Loh; Barbara L Asselin; Ronald D Barr; Luis A Clavell; Craig A Hurwitz; Albert Moghrabi; Yvan Samson; Marshall Schorin; Harvey J Cohen; Stephen E Sallan; Lewis B Silverman
Journal:  J Clin Oncol       Date:  2007-03-01       Impact factor: 44.544

4.  Site of oncologic specialty care for older adolescents in Utah.

Authors:  Karen H Albritton; Charles H Wiggins; Harold E Nelson; Jane C Weeks
Journal:  J Clin Oncol       Date:  2007-10-10       Impact factor: 44.544

5.  Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia.

Authors:  Kheira Beldjord; Sylvie Chevret; Vahid Asnafi; Françoise Huguet; Marie-Laure Boulland; Thibaut Leguay; Xavier Thomas; Jean-Michel Cayuela; Nathalie Grardel; Yves Chalandon; Nicolas Boissel; Beat Schaefer; Eric Delabesse; Hélène Cavé; Patrice Chevallier; Agnès Buzyn; Thierry Fest; Oumedaly Reman; Jean-Paul Vernant; Véronique Lhéritier; Marie C Béné; Marina Lafage; Elizabeth Macintyre; Norbert Ifrah; Hervé Dombret
Journal:  Blood       Date:  2014-04-16       Impact factor: 22.113

6.  Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy.

Authors:  J B Nachman; H N Sather; M G Sensel; M E Trigg; J M Cherlow; J N Lukens; L Wolff; F M Uckun; P S Gaynon
Journal:  N Engl J Med       Date:  1998-06-04       Impact factor: 91.245

7.  Clinical relevance of in vitro drug resistance testing in childhood acute lymphoblastic leukemia: the state of the art.

Authors:  R Pieters; G J Kaspers; E Klumper; A J Veerman
Journal:  Med Pediatr Oncol       Date:  1994

8.  Pharmacokinetics-based integration of multiple doses of intravenous pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemia.

Authors:  Dan Douer; Ibrahim Aldoss; Matthew A Lunning; Patrick W Burke; Laleh Ramezani; Lisa Mark; Janice Vrona; Jae H Park; Martin S Tallman; Vassilios I Avramis; Vinod Pullarkat; Ann M Mohrbacher
Journal:  J Clin Oncol       Date:  2014-02-10       Impact factor: 44.544

9.  Long-term follow-up of adults with acute lymphoblastic leukemia in first remission treated with chemotherapy or bone marrow transplantation. The Acute Lymphoblastic Leukemia Working Committee.

Authors:  M J Zhang; D Hoelzer; M M Horowitz; R P Gale; D Messerer; J P Klein; H Löffler; K A Sobocinski; E Thiel; D J Weisdorf
Journal:  Ann Intern Med       Date:  1995-09-15       Impact factor: 25.391

10.  Outcome for children and young people with Early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003.

Authors:  Katharine Patrick; Rachel Wade; Nick Goulden; Chris Mitchell; Anthony V Moorman; Clare Rowntree; Sarah Jenkinson; Rachael Hough; Ajay Vora
Journal:  Br J Haematol       Date:  2014-04-08       Impact factor: 6.998
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.